Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance

Hamdan, Righab; Nassar, Pierre; Zein, Ali El; Issa, Mohamad; Mansour, Hassan; Saab, Mohamad

doi:10.1016/j.jcrc.2016.09.028

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The delivery was delayed for two days to allow cardiac function to improve. Some case reports showed occurrences of cardiogenic shock during cesarean section [3,16]. Our management was comprehensive, considered, and avoided aggressive exacerbation of cardiac function by cesarean section.…”

Section: Case Presentationmentioning

confidence: 97%

Untitled

2016

Transl Perioper & Pain Med

View full text Add to dashboard Cite

We report a case of peripartum cardiomyopathy (PPCM) in an advanced maternal age (AMA), obese female with multiple risk factors. Early diagnosis and adequate treatment reduce significant patient mortality associated with this condition. In patients with multiple risk factors who present with symptoms of normal pregnancies, PPCM should be ruled out by echocardiogram and N-terminal pro b-type natriuretic peptide (NT-proBNP) quantification. Over a six-month period, the patient's left heart systolic function recovered slowly, although she was clinically asymptomatic. Because of her persistently low ejection fraction (EF) at the threemonth follow-up, we initiated the use of sacubitril/valsartan, which induced cardiac recovery within three weeks. While sacubitril/valsartan has been proven to improve outcomes in heart failure patients, its use should proceed with caution in peripartum patients.

show abstract

Section: Case Presentationmentioning

confidence: 97%

Untitled

2016

Transl Perioper & Pain Med

View full text Add to dashboard Cite

show abstract

Extracorporeal Membrane Oxygenation in Pregnancy

Thompson

2021

Obstetric Catastrophes

View full text Add to dashboard Cite

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

Simon-Freeman¹,

Yang²,

Hameed³

2018

AJP Rep

View full text Add to dashboard Cite

Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy. Data Sources Data were collected from PubMed/MedLine, ClinicalTrials.gov; the years 2007 to 2018 were searched for English-language articles. Search terms: “bromocriptine and peripartum cardiomyopathy”, “bromocriptine and cardiomyopathy.” Methods of Study Selection This search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review. Tabulation, Integration, and Results Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included. Conclusion Bromocriptine seems to be a promising treatment, there is currently insufficient evidence for universal utilization of bromocriptine for all patients with PPCMP. Addition of bromocriptine to the standard heart failure therapy should be individualized.

show abstract

Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance

Cited by 5 publications

References 13 publications

Untitled

Untitled

Extracorporeal Membrane Oxygenation in Pregnancy

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

Contact Info

Product

Resources

About